IDYA · IDEAYA Biosciences, Inc.
$36.23
+3.51% last session
End-of-day data · updated 2026-07-25
Market cap
$3B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-9.7
Dividend yield
—
Beta
-0.09
Avg volume
1M
Employees
0K
2D change
-2.29%
5D change
-0.14%
10D change
-3.65%
30D change
-2.45%
60D change
20.61%
MTD change
-2.13%
YTD change
2.40%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — IDYA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-07
Latest call per bank · past 12 months
RBC Capital
Outperform$48.00
+32.5% vs priceGoldman Sachs
Neutral$35.00
-3.4% vs priceWells Fargo
Overweight$48.00
+32.5% vs priceCitigroup
Buy$65.00
+79.4% vs priceJP Morgan
Overweight$79.00
+118.1% vs priceBarclays
Overweight$40.00
+10.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-07 | RBC Capital | Maintains | Outperform | $53.00 → $48.00 |
| 2026-07-07 | Truist Securities | Maintains | Buy | $65.00 → $63.00 |
| 2026-06-12 | Wedbush | Reiterates | Outperform | $58.00 |
| 2026-06-02 | Wedbush | Reiterates | Outperform | $58.00 |
| 2026-05-07 | Mizuho | Maintains | Outperform | $52.00 → $50.00 |
| 2026-04-14 | Goldman Sachs | Maintains | Neutral | $31.00 → $35.00 |
| 2026-04-14 | Wells Fargo | Maintains | Overweight | $44.00 → $48.00 |
| 2026-04-14 | RBC Capital | Maintains | Outperform | $49.00 → $53.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 55 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 11.1% above the 50-day MA ($32.60).
- Price vs 200-day MA: Trading 11.6% above the 200-day MA ($32.46).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.45) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($22.41) and high ($40.51).
IDYA Price Chart
Loading chart for IDYA…
Fundamentals
About IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$121B 5.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$69B -14.8% YTD
ARGX
argenx SE
$57B 9.2% YTD
RVMD
Revolution Medicines, Inc.
$40B 137.6% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -31.7% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.7% YTD
ROIV
Roivant Sciences Ltd.
$25B 61.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.